Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 166 participants.

Also called NCT05004675

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 166 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05004675
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
France, Germany, Norway, Spain, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05004675. Randomized; quadruple masking; primary purpose treatment. Start 2022-06-20 (actual); primary completion 2024-05-30 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Trial to Evaluate Efficacy and Safety of LIB003 and Inclisiran in High-risk CVD Patients
Acronym
LIBerate-VI
Condition
Hypercholesterolemia
Condition
Atherosclerotic Ischemic Disease
Intervention (Biological)
lerodalcibep
Intervention (Drug)
Inclisiran
Lead sponsor
LIB Therapeutics LLC (class: industry)
Collaborator
Medpace, Inc. (class: industry)

Record details

Record id
cardio:ct-nct05004675
Content hash
23bc366c255af64386c51abc71453ca7f6339b6a4135449b3c44e16ed676af41